Future Alli Actual Use, Label Comprehension Commitments Likely
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline could be asked to conduct more actual use research to support the possible transition of the weight loss drug Xenical (orlistat) from prescription to over-the-counter sale
You may also be interested in...
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6